title: Cutting edge: anti-inflammatory properties of low levels of IFN-gamma.
abstract: Activation of naive T and B cells occurs only within the context of organized lymphoid tissue. Thus, the continuous recirculation of mature lymphocytes is crucial for the development of primary immune response to foreign Ags. We have previously shown that low levels of IFN-gamma inhibit homing of B cells to the secondary lymphoid organs. In this study, we demonstrate that similarly low doses of IFN-gamma down-regulate integrin-mediated adhesion and migration of naive T and Th2 cells, and have a profound effect on the in vivo homing of naive T cells to the lymph nodes. Moreover, we show that these low doses of IFN-gamma have anti-inflammatory effects in an in vivo asthma model. Thus, in contrast to the proinflammatory effects of IFN-gamma at relatively high concentrations, low dose IFN-gamma appears to exert global suppressory effects on T cell trafficking and may have clinical application as an anti-inflammatory agent.
authors.affiliation: Department of Immunology, Weizmann Institute of Science, and Sourasky Medical Center, Tel-Aviv, Israel.
authors.forename: Liat
authors.initials: L
authors.lastname: Flaishon
authors.forename: Ian
authors.initials: I
authors.lastname: Topilski
authors.forename: David
authors.initials: D
authors.lastname: Shoseyov
authors.forename: Rami
authors.initials: R
authors.lastname: Hershkoviz
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fireman
authors.forename: Yoram
authors.initials: Y
authors.lastname: Levo
authors.forename: Sylvia
authors.initials: S
authors.lastname: Marmor
authors.forename: Idit
authors.initials: I
authors.lastname: Shachar
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000494:pharmacology*; D016535:Bronchial Hyperreactivity / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D002448:Cell Adhesion / Q000276:immunology; D002464:Cell Migration Inhibition; D002465:Cell Movement / Q000276:immunology; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D015536:Down-Regulation / Q000276:immunology; D004334:Drug Administration Schedule; D007274:Injections, Intraperitoneal; D016023:Integrins / Q000037:antagonists & inhibitors / Q000502:physiology; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000473:pathology / Q000502:physiology; D018418:Th2 Cells / Q000276:immunology / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016023:Integrins; D007371:Interferon-gamma